4D Molecular Therapeutics FDMT Commitments & Contingencies

Commitments & Contingencies at other companies

Tandem Diabetes CareTNDM

$0—

HagertyHGTY

$0—

Global Net LeaseGNL

$0—

W&T OffshoreWTI

$25.75M+27.5%

FIP

FTAI Infrastructure Inc.FIP

$0—

OGS

ONE GASOGS

$0—

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommitmentsAndContingencies.

The official record: 4D Molecular Therapeutics’s 10-Q, filed August 12, 2021, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's commitments & contingencies.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's commitments & contingencies?: 4D Molecular Therapeutics (FDMT) reported commitments & contingencies of $0 in Q2 2021.